# A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

Source: https://onco.cc/trials/nct04170283/  
OnCo record `nct04170283` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Zanubrutinib and Tislelizumab in advanced solid tumours, run by BeOne Medicines, active and no longer recruiting.

## Summary

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib is a phase 3 interventional study registered as NCT04170283 by BeOne Medicines, with 955 participants enrolled, started 2020-01-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: Zanubrutinib and Tislelizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04170283
- Phase: 3
- Setting: An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
- Sponsor: BeOne Medicines
- Enrolled: 955

## Sources

- ClinicalTrials.gov NCT04170283: https://clinicaltrials.gov/study/NCT04170283

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct04170283.json